Omeros shares oversold, secondary endpoint met, says Maxim Maxim says that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm adds that pain is directly related to inflammation and the surgical process itself. Maxim finds Omeros shares oversold and said it’s a buyer of the stock.
News For OMER From The Last 14 Days
Check below for free stories on OMER the last two weeks.
Subscribe for More Information